<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Hepatitis C, chronic; Ribavirin: chronic hepatitis C; Tribavirin see Ribavirin; Peginterferon alfa; Interferon: peginterferon alfa: chronic hepatitis C; Interferon: alfa: chronic hepatitis C; Boceprevir; Telaprevir" /><meta name="IX" content="Hepatitis C, chronic; Ribavirin: chronic hepatitis C; Peginterferon alfa; Interferon: peginterferon alfa: chronic hepatitis C; Interferon: alfa: chronic hepatitis C; Boceprevir; Telaprevir" /><meta name="IXN" content="Tribavirin see Ribavirin" /><title>5.3.3.2 Chronic hepatitis C: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP3880-chronic-hepatitis-c.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP3880-chronic-hepatitis-c.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP3880-chronic-hepatitis-c.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP3253-infections.htm">5 Infections</a> &gt; <a href="PHP3742-antiviral-drugs.htm">5.3 Antiviral drugs</a> &gt; <a href="PHP3868-viral-hepatitis.htm">5.3.3 Viral hepatitis</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP3874-telbivudine.htm" title="Previous: TELBIVUDINE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP3882-boceprevir.htm" title="Next: BOCEPREVIR">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>5.3.3.2 </span>Chronic hepatitis C</h1><?highlighter on?><div id="pC" class="jN"><p>Before starting treatment, the genotype of the infecting hepatitis C virus should be determined and the viral load measured as this may affect the choice and duration of treatment. A combination of <strong>ribavirin</strong> (see <a title="sub-section: Respiratory syncytial virus" href="PHP3901-respiratory-syncytial-virus.htm">Respiratory Syncytial Virus</a>) and <strong>peginterferon alfa</strong> (<a title="monograph-family: Interferon alfa" href="PHP5666-interferon-alfa.htm">section 8.2.4</a>) is used for the treatment of chronic hepatitis C (see NICE guidance, below). The combination of ribavirin and interferon alfa is less effective than the combination of peginterferon alfa and ribavirin. Peginterferon alfa alone should be used if ribavirin is contra-indicated or not tolerated. Ribavirin monotherapy is ineffective.</p><div id="PHP3881" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Peginterferon alfa and ribavirin for mild chronic hepatitis C (August 2006 and September 2010)</h3><p>The combination of peginterferon alfa and ribavirin can be used for treating mild chronic hepatitis C in patients over 18 years. Alternatively, treatment can be delayed until the disease has reached a moderate stage (‘watchful waiting’). Peginterferon alfa alone can be used if ribavirin is contra-indicated or not tolerated.</p></div><div class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Peginterferon alfa, interferon alfa, and ribavirin for moderate to severe chronic hepatitis C (January 2004 and September 2010)</h3><p>The combination of peginterferon alfa and ribavirin should be used for treating moderate to severe chronic hepatitis C in patients aged over 18 years:</p><ul><li><p>not previously treated with interferon alfa or peginterferon alfa;</p> </li><li><p>treated previously with interferon alfa alone or in combination with ribavirin;</p> </li><li><p>whose condition did not respond to peginterferon alfa alone or to a combination of peginterferon alfa and ribavirin, or responded but subsequently relapsed;</p> </li><li><p>co-infected with HIV.</p> </li></ul><p>Peginterferon alfa alone should be used if ribavirin is contra-indicated or not tolerated. Interferon alfa for either monotherapy or combined therapy should be used only if neutropenia and thrombocytopenia are a particular risk. Patients receiving interferon alfa may be switched to peginterferon alfa.</p><p>Full guidance available at <a href="http://www.nice.org.uk/TA075">www.nice.org.uk/TA075</a>.</p></div><p><strong>Boceprevir</strong> and <strong>telaprevir</strong> are protease inhibitors that inhibit the replication of hepatitis C virus genotype 1, but they are less effective against other genotypes of the virus. Monotherapy is not recommended because there is a high likelihood of resistance developing. Either boceprevir or telaprevir is licensed for use in combination with ribavirin and peginterferon alfa for the treatment of chronic hepatitis C infection of genotype 1 in patients with compensated liver disease; these combinations are more effective than dual therapy with ribavirin and peginterferon alfa. However, triple therapy is associated with a higher incidence and greater severity of anaemia than dual therapy. Neutropenia seems to be more frequent during treatment with regimens containing boceprevir than with those containing telaprevir. Rash is a particular concern with telaprevir, and to a lesser extent with boceprevir.</p><div class="cI"><p class="cAE">NICE guidance</p> <h3 class="cT">Boceprevir or telaprevir for chronic hepatitis C infection of genotype 1 (April 2012)</h3><p>Either boceprevir or telaprevir in combination with ribavirin and peginterferon alfa is an option for the treatment of chronic hepatitis C infection of genotype 1 in adults with compensated liver disease: </p><ul><li><p>who have not been treated previously;</p></li><li><p>in whom previous treatment (e.g. with peginterferon alfa in combination with ribavirin) has failed.</p></li></ul> </div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP3882-boceprevir"><a href="PHP3882-boceprevir.htm" title="BOCEPREVIR">BOCEPREVIR</a></li><li id="_PHP3884-telaprevir"><a href="PHP3884-telaprevir.htm" title="TELAPREVIR">TELAPREVIR</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP3874-telbivudine.htm">Previous: TELBIVUDINE</a> | <a class="top" href="PHP3880-chronic-hepatitis-c.htm#">Top</a> | <a accesskey="]" href="PHP3882-boceprevir.htm">Next: BOCEPREVIR</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>